PURPOSE: Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contributor to response. A detailed assessment of the response dynamics of individual metastasis could provide insight to the systemic and local features that mediate response and resistance to immunotherapy. MATERIALS AND METHODS: Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair deficiency (MMRD) carcinoma treated with PD-1 monotherapy were evaluated independently. Absolute and percent change of each target lesion were quantified at each computed tomography scan using RECIST. Patterns of progression were predefined as systemic or mixed and were correlated with clinical outcomes. RESULTS: A total of 761 individual lesions from 214 patients with NSCLC and 290 lesions from 78 patients with MMRD carcinoma were examined. Individual target lesion responses aligned with best overall response of each patient (85% NSCLC and 93% MMRD lesions responded in patients with partial response/complete response). In responding patients, timing of response was uniform (73% NSCLC and 76% MMRD lesions responded synchronously), and deeper responses were associated with prolonged progression-free survival and overall survival. By contrast, at progression, mixed progression was common (45% of NSCLC and 53% of MMRD) and associated with improved survival compared with those who experienced systemic progression (NSCLC hazard ratio [HR], 0.58; P = .001; MMRD HR, 0.40; P = .07). Organ sites had differential responses, with lymph node and liver metastasis among the most and least responsive, respectively. CONCLUSION: Temporal-spatial patterns of response across individual metastases tend to be uniform, favoring the role of peripheral, clonally directed antitumor immunity as a key mediator of response to PD-1 blockade. In contrast, progression is more heterogeneous, potentially revealing the clinical importance of local features and intertumoral heterogeneity.
PURPOSE: Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contributor to response. A detailed assessment of the response dynamics of individual metastasis could provide insight to the systemic and local features that mediate response and resistance to immunotherapy. MATERIALS AND METHODS:Patients with metastatic non-small-cell lung cancer (NSCLC) or mismatch repair deficiency (MMRD) carcinoma treated with PD-1 monotherapy were evaluated independently. Absolute and percent change of each target lesion were quantified at each computed tomography scan using RECIST. Patterns of progression were predefined as systemic or mixed and were correlated with clinical outcomes. RESULTS: A total of 761 individual lesions from 214 patients with NSCLC and 290 lesions from 78 patients with MMRD carcinoma were examined. Individual target lesion responses aligned with best overall response of each patient (85% NSCLC and 93% MMRD lesions responded in patients with partial response/complete response). In responding patients, timing of response was uniform (73% NSCLC and 76% MMRD lesions responded synchronously), and deeper responses were associated with prolonged progression-free survival and overall survival. By contrast, at progression, mixed progression was common (45% of NSCLC and 53% of MMRD) and associated with improved survival compared with those who experienced systemic progression (NSCLC hazard ratio [HR], 0.58; P = .001; MMRD HR, 0.40; P = .07). Organ sites had differential responses, with lymph node and liver metastasis among the most and least responsive, respectively. CONCLUSION: Temporal-spatial patterns of response across individual metastases tend to be uniform, favoring the role of peripheral, clonally directed antitumor immunity as a key mediator of response to PD-1 blockade. In contrast, progression is more heterogeneous, potentially revealing the clinical importance of local features and intertumoral heterogeneity.
Authors: Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: Mark Ayers; Jared Lunceford; Michael Nebozhyn; Erin Murphy; Andrey Loboda; David R Kaufman; Andrew Albright; Jonathan D Cheng; S Peter Kang; Veena Shankaran; Sarina A Piha-Paul; Jennifer Yearley; Tanguy Y Seiwert; Antoni Ribas; Terrill K McClanahan Journal: J Clin Invest Date: 2017-06-26 Impact factor: 14.808
Authors: P A Knolle; E Schmitt; S Jin; T Germann; R Duchmann; S Hegenbarth; G Gerken; A W Lohse Journal: Gastroenterology Date: 1999-06 Impact factor: 22.682
Authors: Alexander C Huang; Michael A Postow; Robert J Orlowski; Rosemarie Mick; Bertram Bengsch; Sasikanth Manne; Wei Xu; Shannon Harmon; Josephine R Giles; Brandon Wenz; Matthew Adamow; Deborah Kuk; Katherine S Panageas; Cristina Carrera; Phillip Wong; Felix Quagliarello; Bradley Wubbenhorst; Kurt D'Andrea; Kristen E Pauken; Ramin S Herati; Ryan P Staupe; Jason M Schenkel; Suzanne McGettigan; Shawn Kothari; Sangeeth M George; Robert H Vonderheide; Ravi K Amaravadi; Giorgos C Karakousis; Lynn M Schuchter; Xiaowei Xu; Katherine L Nathanson; Jedd D Wolchok; Tara C Gangadhar; E John Wherry Journal: Nature Date: 2017-04-10 Impact factor: 49.962
Authors: Susan N Thomas; Joseph M Rutkowski; Miriella Pasquier; Emma L Kuan; Kari Alitalo; Gwendalyn J Randolph; Melody A Swartz Journal: J Immunol Date: 2012-07-27 Impact factor: 5.422
Authors: Zubin M Bamboat; Jennifer A Stableford; George Plitas; Bryan M Burt; Hoang M Nguyen; Alexander P Welles; Mithat Gonen; James W Young; Ronald P DeMatteo Journal: J Immunol Date: 2009-02-15 Impact factor: 5.422
Authors: Matthew D Hellmann; Tavi Nathanson; Hira Rizvi; Benjamin C Creelan; Francisco Sanchez-Vega; Arun Ahuja; Ai Ni; Jacki B Novik; Levi M B Mangarin; Mohsen Abu-Akeel; Cailian Liu; Jennifer L Sauter; Natasha Rekhtman; Eliza Chang; Margaret K Callahan; Jamie E Chaft; Martin H Voss; Megan Tenet; Xue-Mei Li; Kelly Covello; Andrea Renninger; Patrik Vitazka; William J Geese; Hossein Borghaei; Charles M Rudin; Scott J Antonia; Charles Swanton; Jeff Hammerbacher; Taha Merghoub; Nicholas McGranahan; Alexandra Snyder; Jedd D Wolchok Journal: Cancer Cell Date: 2018-04-12 Impact factor: 31.743
Authors: Alexander C Huang; Robert J Orlowski; Xiaowei Xu; Rosemarie Mick; Sangeeth M George; Patrick K Yan; Sasikanth Manne; Adam A Kraya; Bradley Wubbenhorst; Liza Dorfman; Kurt D'Andrea; Brandon M Wenz; Shujing Liu; Lakshmi Chilukuri; Andrew Kozlov; Mary Carberry; Lydia Giles; Melanie W Kier; Felix Quagliarello; Suzanne McGettigan; Kristin Kreider; Lakshmanan Annamalai; Qing Zhao; Robin Mogg; Wei Xu; Wendy M Blumenschein; Jennifer H Yearley; Gerald P Linette; Ravi K Amaravadi; Lynn M Schuchter; Ramin S Herati; Bertram Bengsch; Katherine L Nathanson; Michael D Farwell; Giorgos C Karakousis; E John Wherry; Tara C Mitchell Journal: Nat Med Date: 2019-02-25 Impact factor: 53.440
Authors: Nicholas D Klemen; Sinchun Hwang; Martina Bradic; Evan Rosenbaum; Mark A Dickson; Mrinal M Gounder; Ciara M Kelly; Mary L Keohan; Sujana Movva; Katherine A Thornton; Ping Chi; Benjamin A Nacev; Jason E Chan; Edmund K Bartlett; Allison L Richards; Samuel Singer; Mark T A Donoghue; William D Tap; Sandra P D'Angelo Journal: Clin Cancer Res Date: 2022-03-01 Impact factor: 12.531
Authors: Angel Qin; Songzhu Zhao; Abdul Miah; Lai Wei; Sandipkumar Patel; Andrew Johns; Madison Grogan; Erin M Bertino; Kai He; Peter G Shields; Gregory P Kalemkerian; Shirish M Gadgeel; Nithya Ramnath; Bryan J Schneider; Khaled A Hassan; Nicholas Szerlip; Zoey Chopra; Sara Journey; Jessica Waninger; Daniel Spakowicz; David P Carbone; Carolyn J Presley; Gregory A Otterson; Michael D Green; Dwight H Owen Journal: J Natl Compr Canc Netw Date: 2021-04-20 Impact factor: 12.693
Authors: Dennis Jones; Zixiong Wang; Ivy X Chen; Sue Zhang; Rohin Banerji; Pin-Ji Lei; Hengbo Zhou; Victoria Xiao; Cecilia Kwong; Jan Willem M van Wijnbergen; Ethel R Pereira; Benjamin J Vakoc; Peigen Huang; Hadi T Nia; Timothy P Padera Journal: Nat Biomed Eng Date: 2021-07-19 Impact factor: 25.671
Authors: Andrew Chow; Sara Schad; Michael D Green; Matthew D Hellmann; Viola Allaj; Nicholas Ceglia; Giulia Zago; Nisargbhai S Shah; Sai Kiran Sharma; Marissa Mattar; Joseph Chan; Hira Rizvi; Hong Zhong; Cailian Liu; Yonina Bykov; Dmitriy Zamarin; Hongyu Shi; Sadna Budhu; Corrin Wohlhieter; Fathema Uddin; Aditi Gupta; Inna Khodos; Jessica J Waninger; Angel Qin; Geoffrey J Markowitz; Vivek Mittal; Vinod Balachandran; Jennifer N Durham; Dung T Le; Weiping Zou; Sohrab P Shah; Andrew McPherson; Katherine Panageas; Jason S Lewis; Justin S A Perry; Elisa de Stanchina; Triparna Sen; John T Poirier; Jedd D Wolchok; Charles M Rudin; Taha Merghoub Journal: Cancer Cell Date: 2021-06-10 Impact factor: 38.585